UnitedHealth Group Incorporated

Fundamentals6.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • High cash flow
  • Elevated leverage
  • Quarterly volatility

AI
AI Summary

6.0

UNH has shifted from a defensive compounder into an execution‑sensitive turnaround where margin recovery now requires a successful Optum Health turnaround, membership stabilization after repricing, and verifiable AI/claims savings to offset weaker MA/Medicaid reimbursement; investors should treat the stock as tactical and monitor sequential margin improvement, early delivery of cost saves, and CMS MA rate signals as the key catalysts. Failure to show those signs or a break below the ~$271 support would likely trigger further downside.

Optum
Regulation
Execution‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High cash flow
  • Elevated leverage
  • Quarterly volatility

UnitedHealth combines dominant scale, strong cash generation and solid returns with a moderate valuation premium but elevated leverage, tight short‑term liquidity and pronounced quarterly earnings volatility.

Scale
Leverage

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Defended mid‑$270s
  • Resistance at ~$290s
  • Rising intraday volatility

UNH is in a modest short-term downtrend over the last month, finding support in the $271–$276 area but capped by resistance near $290–$293 and showing higher volatility that raises whipsaw risk.

Bearish
Neutral
Support Level: $271–$276
Resistance Level: $290–$293

Increased volatility with intraperiod rally to $292.65 and higher whipsaw risk

Sentiment & News

6.0

Key News Insights:

  • Regulatory shock
  • Rising costs
  • AI cost-savings

UnitedHealth faces near-term regulatory and cost pressures that sparked a ~23% share drop, yet investors are split as attractive valuation, a 3% forward dividend and AI-driven cost-savings/management guidance support buy cases amid an ongoing investor probe.

ValueBuy
RegRisk

Near-term sentiment will likely remain pressured by reimbursement and medical-cost risks, but valuation, yield and execution on AI savings could drive selective accumulation over the medium term